Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Nov;98(11):e146-8.
doi: 10.3324/haematol.2013.095372.

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

Etienne Lengline  1 , Kheïra Beldjord, Hervé Dombret, Jean Soulier, Nicolas Boissel, Emmanuelle Clappier
Affiliations
Case Reports

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

Etienne Lengline et al. Haematologica. 2013 Nov.
No abstract available

Keywords: B-cell precursor acute lymphoblastic leukemia; EBF1-PDGFRB; refractory; tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Array-CGH plots showing 5q33 microdeletion that fuses EBF1 and PDGFRB genes. SurePrint G3 180K array, analysis using Agilent Genomic Workbench software with the ADM-2 algorithm (www.agilent.com). (B) RT-PCR of the EBF1-PDGFRB fusion transcript using the following primers: EBF1-forward 5′-AAGAGTGCTTTCGCACCAGT-3; PDGFRB-reverse 5′- GGGCAGAGCATTGCTGTAGA-3′. (C) Electropherogram of the transcript fusion sequence after direct Sanger sequencing of the RT-PCR product.
Figure 2.
Figure 2.
Minimal residual disease (MRD) in bone marrow as a function of time, evaluated by real-time genomic quantification of molecular markers according to EuroMRD guidelines. The molecular markers used were a VD2DD3 rearrangement and intragenic IKZF1 deletion Δ(2–7), which gave consistent results. The dotted line indicates a decrease in MRD below the limit of quantitative range (5×10−5). The gray zone represents the range below the sensitivity of the technique (10−5). The therapeutic interventions are indicated at the top of the graph. They include induction phase from FRALLE 2000 group B2 from Day 1 to Day 29, first consolidation block with high-dose cytarabine, etoposide and dexametha-sone (VEDA) from Day 53 to Day 60, Hyper-CVAD course B (high-dose cytarabine and methotrexate) from Day 73 to Day 76, four weekly pulses of vincristine and dexamethasone from Day 93 to Day 122. Allogeneic BMT was performed at day 133 after a conditioning regimen consisting of total body irradiation and cyclophosphamide. MRD was assessed at Day 42 (post-induction), Day 73 (after first consolidation block), Day 93 (after second consolidation course), Day 107, Day 126 (pre-BMT), Day 164 (30 days post-BMT) and Day 239 (105 days post-BMT).
See this image and copyright information in PMC

References

    1. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153–66 - PMC - PubMed
    1. Strullu M, Corradini N, Audrain M, Orsonneau JL, Bouige D, Thomare P, et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2010;51(8):1464–72 - PubMed
    1. Lin H, Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature. 1995;376(6537):263–7 - PubMed
    1. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2):307–16 - PubMed
    1. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA. 1996;93(25): 14845–50 - PMC - PubMed

MeSH terms